A, B, C…γ!
2000; Lippincott Williams & Wilkins; Volume: 20; Issue: 6 Linguagem: Húngaro
10.1161/01.atv.20.6.1423
ISSN1524-4636
AutoresAlan R. Tall, Christian Schindler,
Tópico(s)Peroxisome Proliferator-Activated Receptors
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 20, No. 6A, B, C…γ! Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBA, B, C…γ! Alan R. Tall and Christian W. Schindler Alan R. TallAlan R. Tall From the Departments of Medicine (A.R.T., C.W.S.) and Microbiology (C.W.S.), Columbia University, New York. and Christian W. SchindlerChristian W. Schindler From the Departments of Medicine (A.R.T., C.W.S.) and Microbiology (C.W.S.), Columbia University, New York. Originally published1 Jun 2000https://doi.org/10.1161/01.ATV.20.6.1423Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1423–1424Tangier disease is a rare recessive genetic disorder, characterized by extremely low HDL levels, accumulation of cholesterol esters in macrophages, and premature coronary heart disease.1 The observation that fibroblasts from Tangier disease patients have a marked defect in efflux of cholesterol and phospholipids to apoA-I provided a key insight into the underlying defect.2 Recently, 3 different groups made the exciting discovery that Tangier disease is caused by mutations in an adenosine triphosphate (ATP) binding cassette transporter, ABC1.345 Thus, it is likely that ABC1 mediates or regulates the efflux of cellular cholesterol and phospholipids to apoA-I. Although ABC1 is widely expressed, the brunt of the defect is seen in macrophages, indicating their absolute dependence on an active cholesterol efflux pathway. The nature of the ABC1 molecule and the consequences of its mutation provide important evidence that reverse cholesterol transport underlies the atheroprotective effect of HDL. Already a multiplicity of ABC1 mutations have been described.345 Importantly, heterozygous mutations can also cause the more common forms of familial hypoalphalipoproteinemia.4The ABC1 molecule contains 2 clusters of 6 transmembrane domains and internal loops with nucleotide binding motifs. Similar ABC transporters have been described to act as phospholipid flippases, ie, they utilize ATP to transfer phospholipids from the inner to the outer leaflet of cellular membranes.6 Although ABC1 is expressed in the plasma membrane,7 it could also be active at intracellular sites such as the golgi. Based on a detailed electron microscopic analysis of a related ABC transporter, the multidrug resistance P-glycoprotein, it is likely that the 2 clusters of transmembrane domains surround a large aqueous chamber that opens to the outside of the cell through a pore.8 The limiting diameter of this pore may explain why ABC1 preferentially transfers lipids to apoA-I and possibly small HDL. The central chamber also interfaces with the hydrophobic interior of the membrane but not with the cytoplasmic face of the inner membrane leaflet, suggesting a route for phospholipid flipping. In contrast to the active efflux mediated by ABC1, the passive exchange of free cholesterol between HDL and cellular membranes may be facilitated by scavenger receptor BI (SRBI).9The low HDL in Tangier disease is due to hypercatabolism of apoA-I, which is produced in the liver and intestine and is the main HDL apolipoprotein.10 ApoA-I appears to interact with ABC1 on cell surfaces absorbing lipid and giving rise to small HDL particles. Subsequently, in the circulation phospholipid transfer protein moves phospholipids from triglyceride-rich lipoproteins onto the nascent HDL, and lecithin:cholesterol acyltransferase generates cholesterol ester giving rise to the mature HDL particle.11 Upregulation of ABC1 expression is likely to enhance cholesterol efflux from macrophage foam cells and may also result in increased HDL levels, especially in settings in which there is increased formation of free apoA-I or small HDL in the bloodstream. This might include the common atherogenic hypertriglyceridemia-low HDL human condition, in which cholesterol ester transfer protein and hepatic lipase act together to produce small HDL or free apoA-I.12The ABC1 molecule is likely to be highly regulated by a variety of different mechanisms.13 In certain cells ABC1 is upregulated by cAMP treatment,7 which likely explains the earlier observations that cAMP treatment of RAW macrophages increases the efflux of cholesterol to apolipoproteins and HDL.14 ABC1 is also markedly upregulated by cholesterol loading of cells, an effect opposed by HDL-mediated cholesterol efflux.13 This indicates a positive sterol feedback control loop regulating ABC1 gene expression. Recently other molecules involved in the reverse cholesterol transport pathway (CETP, cyp7a) have been shown to be upregulated by the nuclear hormone transcription factors, LXRs, which heterodimerize with RXR and are activated by hydroxylated sterols.1516 Thus, LXRs may help to coordinate multiple steps in the reverse cholesterol transport pathway, including the regulation of ABC1 expression by sterols. ABC1 may also be upregulated on a posttranscriptional level, because it is phosphorylated by a protein kinase A mechanism.17In the article in this issue by Panousis and Zuckerman,18 ABC1 mRNA is shown to be markedly downregulated by interferon γ (IFN-γ) treatment of thioglycollate-elicited mouse peritoneal macrophages. This effect was seen in cells under basal conditions and also after upregulation of ABC1 expression by cholesterol loading, suggesting that IFN-γ and sterols mediate regulation by different mechanisms. This decrease in ABC1 mRNA was not mediated by other cytokines, and IFN-γ treatment did not influence the expression of another ABC transporter, TAP, indicating specificity of the effect. Although the authors did not measure ABC1 protein expression, they were able to demonstrate that IFN-γ treatment produced a profound defect in the efflux of cholesterol to apoA-I and a less marked decrease in efflux of cholesterol to HDL. Because these changes are characteristic of ABC-1-mediated cholesterol efflux, it is likely that IFN-γ treatment led to a decrease in functional ABC-1 protein being expressed in macrophages.This study was conducted as a follow-up to an earlier paper in which the authors first showed that IFN-γ treatment produced a defect in cholesterol efflux to HDL. It was found that IFN-γ caused a moderate increase in ACAT-1 mRNA expression and that ACAT activity was increased about two-fold in a whole cell ACAT assay. It is likely that the increased activity reflected both an increase in ACAT mRNA as well as an increase in intracellular pools of cholesterol that act as ACAT substrates, secondary to the decrease in active ABC1.IFN-γ has been observed to regulate a number of other genes involved in lipid metabolism, providing some intriguing parallels to its regulation of ABC1. These genes include scavenger receptor A and CD36 in macrophages, collagen production in smooth muscle cells, and apoA-IV expression in hepatocytes. In each case, IFN-γ has been shown to downregulate the expression of these genes.1420 This contrasts with the classical ability of IFN-γ to upregulate the expression of a large number of proinflammatory genes (eg, iNOS, TAP1, and MCH class II) through the transcription factor Stat1.21 These proinflammatory activities may contribute to atherosclerosis as well. A number of potential mechanisms have emerged on how IFN-γ signaling may antagonize the expression of some genes. This includes competition for rate limiting components of the basal transcription machinery, upregulation of inhibitory molecules, and of note a direct antagonism of interleukin 4 (IL-4) stimulated signaling.2122 This later observation may provide some insight into the regulation of ABC1. IL-4 has recently been shown to stimulate expression of CD36, a receptor for the uptake of modified apoB containing lipoproteins, through the coordinate induction of 12/15-lipoxygenase and peroxisome proliferated activated receptor–γ, a nuclear hormone receptor.23 IFN-γ antagonizes IL-4 dependent expression of 15-lipoxygenase (the human equivalent of 12/15-lipoxygenase), so perhaps the ability of IFN-γ to antagonize the cholesterol induced expression of ABC1 may be achieved through the downregulation of 12/15 lipoxygenase.Although IFN-γ has a number of complex, potentially opposing effects, which may influence atherogenesis, the decrease in atherosclerosis in IFN-γ receptor/apoE double KO mice indicates that it has a predominant proatherogenic role in vivo.24 The downregulation of ABC1 by IFN-γ may now be added to the list of its proatherogenic effects. These are important observations that may serve to link an arterial wall inflammatory response involving interferon-producing T cells with a defect in reverse cholesterol transport. ABC1 emerges as an attractive target for pharmacological upregulation because this should enhance cholesterol removal from macrophage foam cells, as well as increase HDL levels. The marked regulation of ABC1 by cytokines and cellular cholesterol stores suggests that it may be possible to achieve this through a transcriptional mechanism.FootnotesCorrespondence to Alan R. Tall, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032. References 1 Schaefer EJ, Zech LA, Schwartz DE, Brewer HB Jr. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med..1980; 93:261–266.CrossrefMedlineGoogle Scholar2 Francis GA, Knopp RH, Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J Clin Invest..1995; 96:78–87.CrossrefMedlineGoogle Scholar3 Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet..1999; 22:347–351.CrossrefMedlineGoogle Scholar4 Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Oulette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop P, Pimstone S, Kastelein JJ, Hayden MR, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet..1999; 22:336–345.CrossrefMedlineGoogle Scholar5 Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet..1999; 22:352–355.CrossrefMedlineGoogle Scholar6 van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell..1996; 87:507–517.CrossrefMedlineGoogle Scholar7 Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway [See comments]. J Clin Invest..1999; 104:R25–R31.CrossrefMedlineGoogle Scholar8 Rosenberg MF, Callaghan R, Ford RC, Higgins CF. Structure of the multidrug resistance P-glycoprotein to 2.5 nM resolution determined by electron microscopy and image analysis. J Biol Chem..1997; 272:10685–10694.CrossrefMedlineGoogle Scholar9 Ji Y, Jian B, Wang N, Sun Y, Moya ML, Phillips MC, Rothblat GH, Swaney JB, Tall AR. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem..1997; 272:20982–20985.CrossrefMedlineGoogle Scholar10 Schaefer EJ, Anderson DW, Zech LA, Lindgren FT, Bronzert TB, Rubalcaba EA, Brewer HB Jr. Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. J Lipid Res..1981; 22:217–228.CrossrefMedlineGoogle Scholar11 Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest..1999; 103:907–914.CrossrefMedlineGoogle Scholar12 Clay MA, Newnham HH, Forte TM, Barter PI. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim Biophys Acta..1992; 1124:52–1128.CrossrefMedlineGoogle Scholar13 Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, Kaminski WE, Schmitz G. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun..1999; 257:29–33.CrossrefMedlineGoogle Scholar14 Smith JD, Miyata M, Ginsberg M, Grigaux C, Shmookler E, Plump AS. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J Biol Chem..1996; 271:30647–30655.CrossrefMedlineGoogle Scholar15 Peet DJ, Janowski BA, Mangelsdorf DJ. The LXRs: a new class of oxysterol receptors. Curr Opin Genet Dev..1998; 8:571–575.CrossrefMedlineGoogle Scholar16 Luo Y, Tall AR. Sterol upregulation of human CETP gene expression in vitro and in transgenic mice by an LXR element. J Clin Invest..2000; 105:513–520.CrossrefMedlineGoogle Scholar17 Becq F, Hamon Y, Bajetto A, Gola M, Verrier B, Chimini G. ABC1, an ATP binding cassette transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes. J Biol Chem..1997; 272:2695–2699.CrossrefMedlineGoogle Scholar18 Panousis CG, Zuckerman SH. Interferon-γ induces downregulation of Tangier disease gene (ATP-binding-cassette transporter-1) in macrophage-derived foam cells. Arterioscler Thromb Vasc Biol..2000; 20:1565–1571.CrossrefMedlineGoogle Scholar19 Hansson GK. Atherosclerosis: cell biology and lipoproteins [Editorial]. Curr Opin Lipidol..1998; 9:73–75.CrossrefMedlineGoogle Scholar20 Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol..1997; 8:301–311.CrossrefMedlineGoogle Scholar21 Schindler C, Strehlow I. Cytokines and STAT signaling. Adv Pharmacol..2000; 47:113–174.MedlineGoogle Scholar22 Conrad DJ, Kuhn H, Mulkins M, Highland E, Sigal E. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci U S A..1992; 89:217–221.CrossrefMedlineGoogle Scholar23 Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, Glass CK. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature..1999; 400:378–382.CrossrefMedlineGoogle Scholar24 Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-γ potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest..1997; 99:2752–2761.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Toth P (2001) High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects, Disease-a-Month, 10.1067/mda.2001.118859, 47:8, (365-416), Online publication date: 1-Aug-2001. Song L, Leung C and Schindler C (2001) Lymphocytes are important in early atherosclerosis, Journal of Clinical Investigation, 10.1172/JCI200111380, 108:2, (251-259), Online publication date: 15-Jul-2001. Song L, Leung C and Schindler C (2001) Lymphocytes are important in early atherosclerosis, Journal of Clinical Investigation, 10.1172/JCI11380, 108:2, (251-259), Online publication date: 15-Jul-2001. June 2000Vol 20, Issue 6 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.20.6.1423 Originally publishedJune 1, 2000 KeywordsABC1atherosclerosisHDLfoam cellLXRPDF download Advertisement
Referência(s)